Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with protease inhibitors‐based direct‐acting antivirals?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with protease inhibitors‐based direct‐acting antivirals?

Published:2022-03-16 Issue:5 Volume:42 Page:1207-1208
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver International

Author:

Wong Yu Jun¹²^ORCID,Nguyen Mindie H.³⁴^ORCID

Affiliation:

1. Department of Gastroenterology and Hepatology Changi General Hospital Singapore

2. Duke‐NUS Medical School Singapore

3. Division of Gastroenterology and Hepatology, Department of Medicine Stanford University Medical Center Palo Alto California USA

4. Department of Epidemiology and Population Health Stanford University Medical Center Palo Alto California USA

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/liv.15214

Reference5 articles.

1. Real‐world effectiveness and safety of direct‐acting antivirals in patients with cirrhosis and history of hepatic decompensation: Epi‐Ter2 Study

2. EASL recommendations on treatment of hepatitis C: Final update of the series☆

3. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity—LINA cohort)

4. Safety of Hepatitis C Viral Protease Inhibitors in Compensated Cirrhotics: Lingering Concerns Put to Rest?

5. Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study;Hepatology International;2023-06-05

2. Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor‐experienced patients with hepatitis C: Real‐world data from a multicenter Asian registry;Journal of Gastroenterology and Hepatology;2022-06-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3